Matching cancer patients with targeted therapies based on their molecular profiles

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to personalize cancer treatment by identifying actionable molecular alterations in patients with advanced solid tumors or hematological malignancies. Using next-generation sequencing and immunological profiling, the study will analyze tumor and blood samples to create a comprehensive molecular profile for each patient. This profile will help clinicians match patients to specific early phase clinical trials that are most likely to benefit them based on their unique genetic characteristics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years,
2. Histology: solid malignant tumor or hematological malignancy,
3. Deleted MSA9
4. Deleted MSA9,
5. Deleted MSA9,
6. Deleted MSA9,
7. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code),
8. Voluntary signed and dated written informed consent prior to any study specific procedure.

Exclusion Criteria:

1. Deleted MSA9
2. Deleted MSA9
3. Deleted MSA9
4. Deleted MSA9
5. Deleted MSA9
6. Deleted MSA9
7. Deleted MSA9
8. Deleted MSA9
9. Individuals deprived of liberty or placed under guardianship
10. Pregnant or breast feeding women,
11. Previous enrolment in the present study.

Where it's running

• Centre Hospitalier de la Côte Basque
  Bayonne, France Recruiting
• Clinique Tivoli-Ducos
  Bordeaux, France Recruiting
• Institut Bergonie
  Bordeaux, France Recruiting
• Polyclinique Bordeaux Nord Aquitaine
  Bordeaux, France Recruiting
• Clinique Marzet
  Pau, France Recruiting
• Centre Hospitalier de Pau
  Pau, France Not yet recruiting

Study contacts

• Study coordinator: Antoine ITALIANO, MD, PhD
• Email: a.italiano@bordeaux.unicancer.fr

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing OT-A201 for treating blood cancers and solid tumors

  This study is testing a new treatment called OT-A201 to see if it can safely help people with blood cancers and solid tumors that haven't responded to other treatments.

  Recruiting at 4 sites Phase 1 Onward Therapeutics · Montpellier and 3 other locations · NCT05828459

• Middle East study of bloodstream infections in blood cancer patients and HSCT recipients

  This is an observational study to see how bloodstream infections affect adults with blood cancers or after stem cell transplants across several Middle East countries.

  Recruiting at 9 sites Hamad Medical Corporation · Amman and 8 other locations · NCT07900542

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• FAPI PET imaging with FAPI-RuiJ and FAPI-04 in solid tumors

  This study tests two FAP-targeted PET tracers (FAPI-RuiJ and FAPI-04) to see which better detects, stages, and monitors solid tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07776899

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.